
RenovoRx (RNXT) Stock Forecast & Price Target
RenovoRx (RNXT) Analyst Ratings
Bulls say
RenovoRx Inc. demonstrated notable revenue growth in Q2, achieving $422K, a substantial increase from $197K in Q1. The company is forecasted to experience significant revenue expansion, with projections of $1.3 million in 2025 and $4.5 million in 2026. This anticipated growth is underpinned by RenovoRx's innovative proprietary therapies designed to address high unmet medical needs in cancer treatment, offering a promising outlook for the company's financial performance moving forward.
Bears say
RenovoRx reported revenue of $0.3 million to $0.4 million alongside a net loss of $2.9 million, which resulted in an earnings per share (EPS) of $(0.08) and did not deviate from consensus estimates. The company operates in the challenging field of pancreatic cancer treatment, which has the most dismal 5-year survival rate of just 12%, underscoring the high unmet medical need and potential market difficulties. While there are considerations for growth prospects and valuation, the persistent net losses and tepid revenue performance highlight fundamental concerns that may warrant a negative outlook on the company’s financial viability.
This aggregate rating is based on analysts' research of RenovoRx and is not a guaranteed prediction by Public.com or investment advice.
RenovoRx (RNXT) Analyst Forecast & Price Prediction
Start investing in RenovoRx (RNXT)
Order type
Buy in
Order amount
Est. shares
0 shares